Published in N Engl J Med on March 21, 2013
An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial (MAL059) | NCT00872963
Efficacy and safety of the RTS,S/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med (2014) 2.79
Gut microbiota elicits a protective immune response against malaria transmission. Cell (2014) 2.48
Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial. Lancet Infect Dis (2015) 1.97
Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children. N Engl J Med (2016) 1.73
Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine: a systematic comparison of predictions from four mathematical models. Lancet (2015) 1.69
Identification of Novel Pre-Erythrocytic Malaria Antigen Candidates for Combination Vaccines with Circumsporozoite Protein. PLoS One (2016) 1.39
The interplay between drug resistance and fitness in malaria parasites. Mol Microbiol (2013) 1.35
Adjuvant-specific regulation of long-term antibody responses by ZBTB20. J Exp Med (2014) 1.25
Looking under the skin: the first steps in malarial infection and immunity. Nat Rev Microbiol (2013) 1.20
Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection. J Clin Invest (2014) 1.14
Immunization with a functional protein complex required for erythrocyte invasion protects against lethal malaria. Proc Natl Acad Sci U S A (2014) 1.12
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals. J Infect Dis (2014) 1.09
Hot spot or not: a comparison of spatial statistical methods to predict prospective malaria infections. Malar J (2014) 1.09
A combined analysis of immunogenicity, antibody kinetics and vaccine efficacy from phase 2 trials of the RTS,S malaria vaccine. BMC Med (2014) 1.07
Community perceptions of a malaria vaccine in the Kintampo districts of Ghana. Malar J (2013) 1.00
Variant surface antigens of malaria parasites: functional and evolutionary insights from comparative gene family classification and analysis. BMC Genomics (2013) 1.00
Model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infect Immun (2013) 0.99
Differing patterns of selection and geospatial genetic diversity within two leading Plasmodium vivax candidate vaccine antigens. PLoS Negl Trop Dis (2014) 0.96
Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors. J Med Chem (2014) 0.96
The March Toward Malaria Vaccines. Am J Prev Med (2015) 0.96
The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models. BMC Med (2015) 0.96
Can immunological principles and cross-disciplinary science illuminate the path to vaccines for HIV and other global health challenges? Philos Trans R Soc Lond B Biol Sci (2015) 0.95
The march toward malaria vaccines. Vaccine (2015) 0.95
Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. Malar J (2014) 0.95
Memory B-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization. J Infect Dis (2014) 0.94
Peripheral blood monocyte-to-lymphocyte ratio at study enrollment predicts efficacy of the RTS,S malaria vaccine: analysis of pooled phase II clinical trial data. BMC Med (2013) 0.94
Interrogating the Plasmodium Sporozoite Surface: Identification of Surface-Exposed Proteins and Demonstration of Glycosylation on CSP and TRAP by Mass Spectrometry-Based Proteomics. PLoS Pathog (2016) 0.91
Antimalarial Drug Resistance: Literature Review and Activities and Findings of the ICEMR Network. Am J Trop Med Hyg (2015) 0.91
Implications of the licensure of a partially efficacious malaria vaccine on evaluating second-generation vaccines. BMC Med (2013) 0.91
Synergistic and antagonistic interactions between bednets and vaccines in the control of malaria. Proc Natl Acad Sci U S A (2015) 0.91
Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice. Proc Natl Acad Sci U S A (2014) 0.91
Malaria drives T cells to exhaustion. Front Microbiol (2014) 0.90
Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants. J Biol Chem (2015) 0.88
Comparative population structure of Plasmodium falciparum circumsporozoite protein NANP repeat lengths in Lilongwe, Malawi. Sci Rep (2013) 0.88
Systems-level analysis of innate immunity. Annu Rev Immunol (2014) 0.88
Targeting regulatory T cells to improve vaccine immunogenicity in early life. Front Microbiol (2014) 0.88
Novel approaches to identify protective malaria vaccine candidates. Front Microbiol (2014) 0.87
Using mutagenesis and structural biology to map the binding site for the Plasmodium falciparum merozoite protein PfRh4 on the human immune adherence receptor. J Biol Chem (2013) 0.86
Impact of Schistosoma mansoni on malaria transmission in Sub-Saharan Africa. PLoS Negl Trop Dis (2014) 0.86
Age-shifting in malaria incidence as a result of induced immunological deficit: a simulation study. Malar J (2015) 0.85
Infectious Diseases of Poverty in Children: A Tale of Two Worlds. Pediatr Clin North Am (2016) 0.85
The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine. PLoS One (2015) 0.85
Diversity-oriented synthesis-facilitated medicinal chemistry: toward the development of novel antimalarial agents. J Med Chem (2014) 0.83
P. falciparum and P. vivax Epitope-Focused VLPs Elicit Sterile Immunity to Blood Stage Infections. PLoS One (2015) 0.83
Discovery of Novel Plasmodium falciparum Pre-Erythrocytic Antigens for Vaccine Development. PLoS One (2015) 0.82
A pantetheinase-resistant pantothenamide with potent, on-target, and selective antiplasmodial activity. Antimicrob Agents Chemother (2015) 0.81
The case for a rational genome-based vaccine against malaria. Front Microbiol (2015) 0.81
A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys. Infect Immun (2014) 0.81
New insight-guided approaches to detect, cure, prevent and eliminate malaria. Protoplasma (2014) 0.81
Open Source Drug Discovery: Highly Potent Antimalarial Compounds Derived from the Tres Cantos Arylpyrroles. ACS Cent Sci (2016) 0.80
Successful vaccines for naturally occurring protozoal diseases of animals should guide human vaccine research. A review of protozoal vaccines and their designs. Parasitology (2014) 0.79
Malaria vaccine development and how external forces shape it: an overview. Int J Environ Res Public Health (2014) 0.79
Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin. Clin Vaccine Immunol (2013) 0.79
Identifying children with excess malaria episodes after adjusting for variation in exposure: identification from a longitudinal study using statistical count models. BMC Med (2015) 0.78
Protective immunity to liver-stage malaria. Clin Transl Immunology (2016) 0.78
The innate and adaptive response to mosquito saliva and Plasmodium sporozoites in the skin. Ann N Y Acad Sci (2015) 0.78
Mice lacking Programmed cell death-1 show a role for CD8(+) T cells in long-term immunity against blood-stage malaria. Sci Rep (2016) 0.78
Assessment of parental perception of malaria vaccine in Tanzania. Malar J (2015) 0.78
Blood Stage Malaria Disrupts Humoral Immunity to the Pre-erythrocytic Stage Circumsporozoite Protein. Cell Rep (2016) 0.77
Parasites: what are they good for? Curr Immunol Rev (2013) 0.76
Mosquito Akirin as a potential antigen for malaria control. Malar J (2014) 0.76
CD8(+) T Cell Responses to Plasmodium and Intracellular Parasites. Curr Immunol Rev (2013) 0.76
Effect of ingested human antibodies induced by RTS, S/AS01 malaria vaccination in children on Plasmodium falciparum oocyst formation and sporogony in mosquitoes. Malar J (2014) 0.76
Letters to the editor. Ochsner J (2013) 0.75
The time-course of protection of the RTS,S vaccine against malaria infections and clinical disease. Malar J (2015) 0.75
Multi-year optimization of malaria intervention: a mathematical model. Malar J (2016) 0.75
Hidden reservoir of resistant parasites: the missing link in the elimination of falciparum malaria. Infect Dis Poverty (2017) 0.75
Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites: Naturally Acquired Humoral Immune Response and B-Cell Epitope Mapping in Brazilian Amazon Inhabitants. Front Immunol (2017) 0.75
Advances in genetics and genomics: use and limitations in achieving malaria elimination goals. Pathog Glob Health (2015) 0.75
Mosquito bite immunization with radiation-attenuated Plasmodium falciparum sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. Malar J (2016) 0.75
Antimalarial activity of tulathromycin in a murine model of malaria. Antimicrob Agents Chemother (2015) 0.75
Antibody and T cell responses in reciprocal prime-boost studies with full-length and truncated merozoite surface protein 1-42 vaccines. PLoS One (2013) 0.75
Malaria Parasites: The Great Escape. Front Immunol (2016) 0.75
Co-expression of Interleukin-15 Enhances the Protective Immune Responses Induced by Immunization with a Murine Malaria MVA-Based Vaccine Encoding the Circumsporozoite Protein. PLoS One (2015) 0.75
Measurement of ex vivo ELISpot interferon-gamma recall responses to Plasmodium falciparum AMA1 and CSP in Ghanaian adults with natural exposure to malaria. Malar J (2016) 0.75
Acceptance of a malaria vaccine by caregivers of sick children in Kenya. Malar J (2014) 0.75
A monoclonal antibody-based immunoassay to measure the antibody response against the repeat region of the circumsporozoite protein of Plasmodium falciparum. Malar J (2016) 0.75
Discriminating Protective from Nonprotective Plasmodium-Specific CD8+ T Cell Responses. J Immunol (2016) 0.75
Modeling of human M1 aminopeptidases for in silico screening of potential Plasmodium falciparum alanine aminopeptidase (PfA-M1) specific inhibitors. Bioinformation (2014) 0.75
Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-Immune Adults: A Phase 1, Double-Blinded Placebo Controlled Dosage Escalation Study. PLoS One (2016) 0.75
Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation. PLoS One (2016) 0.75
Unique aspects of the perinatal immune system. Nat Rev Immunol (2017) 0.75
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
The decline in paediatric malaria admissions on the coast of Kenya. Malar J (2007) 7.45
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis (2011) 2.79
Spatial variation of malaria incidence in young children from a geographically homogeneous area with high endemicity. J Infect Dis (2008) 2.68
The microepidemiology of malaria and its importance to malaria control. Trans R Soc Trop Med Hyg (1989) 2.57
Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis (2009) 2.36
Direct and indirect effects in vaccine efficacy and effectiveness. Am J Epidemiol (1991) 2.08
Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg (1990) 1.85
Quantitation of Plasmodium falciparum sporozoites transmitted in vitro by experimentally infected Anopheles gambiae and Anopheles stephensi. Am J Trop Med Hyg (1991) 1.60
Heterogeneity in malaria exposure and vaccine response: implications for the interpretation of vaccine efficacy trials. Malar J (2010) 1.42
Estimating individual exposure to malaria using local prevalence of malaria infection in the field. PLoS One (2012) 1.24
Estimation of intervention effects using first or multiple episodes in clinical trials: The Andersen-Gill model re-examined. Stat Med (2010) 1.11
What is the efficacy of the RTS,S malaria vaccine? BMJ (2011) 1.01
Interpreting vaccine efficacy. Clin Infect Dis (2005) 1.01
Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med (2005) 13.27
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med (2011) 10.79
The pathogenic basis of malaria. Nature (2002) 10.44
Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet (2004) 9.24
Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet (2008) 8.50
The decline in paediatric malaria admissions on the coast of Kenya. Malar J (2007) 7.45
Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N Engl J Med (2008) 7.28
Assessment of inpatient paediatric care in first referral level hospitals in 13 districts in Kenya. Lancet (2004) 7.13
Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis (2009) 6.90
A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med (2012) 6.64
The consequences of reducing transmission of Plasmodium falciparum in Africa. Adv Parasitol (2002) 6.01
Immunity to malaria: more questions than answers. Nat Immunol (2008) 5.71
Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet (2007) 4.83
Evidence for the involvement of VAR2CSA in pregnancy-associated malaria. J Exp Med (2004) 4.76
Bacteraemia in Kenyan children with sickle-cell anaemia: a retrospective cohort and case-control study. Lancet (2009) 4.76
Case definitions of clinical malaria under different transmission conditions in Kilifi District, Kenya. J Infect Dis (2005) 4.44
Analysis of Plasmodium falciparum diversity in natural infections by deep sequencing. Nature (2012) 4.37
Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N Engl J Med (2008) 4.35
Genome-wide and fine-resolution association analysis of malaria in West Africa. Nat Genet (2009) 4.30
A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet (2007) 4.23
Negative epistasis between the malaria-protective effects of alpha+-thalassemia and the sickle cell trait. Nat Genet (2005) 4.22
Delivery of paediatric care at the first-referral level in Kenya. Lancet (2004) 4.16
Epidemic multiple drug resistant Salmonella Typhimurium causing invasive disease in sub-Saharan Africa have a distinct genotype. Genome Res (2009) 3.99
Relation between falciparum malaria and bacteraemia in Kenyan children: a population-based, case-control study and a longitudinal study. Lancet (2011) 3.78
Stable and unstable malaria hotspots in longitudinal cohort studies in Kenya. PLoS Med (2010) 3.78
Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. Immunity (2005) 3.62
Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun (2008) 3.51
Human antibodies to recombinant protein constructs of Plasmodium falciparum Apical Membrane Antigen 1 (AMA1) and their associations with protection from malaria. Vaccine (2004) 3.51
Men who have sex with men and HIV/AIDS in sub-Saharan Africa. Lancet (2009) 3.51
Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell (2013) 3.49
Use of clinical syndromes to target antibiotic prescribing in seriously ill children in malaria endemic area: observational study. BMJ (2005) 3.34
CISH and susceptibility to infectious diseases. N Engl J Med (2010) 3.31
Burden, features, and outcome of neurological involvement in acute falciparum malaria in Kenyan children. JAMA (2007) 3.29
Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet (2004) 3.25
HIV-1 infection in high risk men who have sex with men in Mombasa, Kenya. AIDS (2007) 3.22
Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases. J Infect Dis (2005) 3.12
Immunization coverage and risk factors for failure to immunize within the Expanded Programme on Immunization in Kenya after introduction of new Haemophilus influenzae type b and hepatitis b virus antigens. BMC Public Health (2006) 3.01
HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis (2009) 2.80
Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS One (2009) 2.79
Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. Lancet Infect Dis (2011) 2.79
Quantitative real-time polymerase chain reaction for malaria diagnosis and its use in malaria vaccine clinical trials. Am J Trop Med Hyg (2005) 2.77
'Are you on the market?': a capture-recapture enumeration of men who sell sex to men in and around Mombasa, Kenya. AIDS (2007) 2.76
Clinical features and pathogenesis of severe malaria. Trends Parasitol (2004) 2.73
Clinical research in resource-limited settings: enhancing research capacity and working together to make trials less complicated. PLoS Negl Trop Dis (2010) 2.68
Profile: The Kilifi Health and Demographic Surveillance System (KHDSS). Int J Epidemiol (2012) 2.64
Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A (2005) 2.57
Transient cross-reactive immune responses can orchestrate antigenic variation in malaria. Nature (2004) 2.56
Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial. Lancet Infect Dis (2011) 2.54
Heritability of malaria in Africa. PLoS Med (2005) 2.49
Clinical algorithms for malaria diagnosis lack utility among people of different age groups. Trop Med Int Health (2005) 2.46
Malaria in Africa: progress and prospects in the decade since the Abuja Declaration. Lancet (2010) 2.41
Taking social relationships seriously: lessons learned from the informed consent practices of a vaccine trial on the Kenyan Coast. Soc Sci Med (2008) 2.39
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Antimicrob Agents Chemother (2009) 2.36
Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J Infect Dis (2009) 2.36
Iron deficiency and malaria among children living on the coast of Kenya. J Infect Dis (2004) 2.34
A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya. PLoS Clin Trials (2006) 2.33
IgG antibody responses to Plasmodium falciparum merozoite antigens in Kenyan children have a short half-life. Malar J (2007) 2.30
Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg (2008) 2.29
Developing and introducing evidence based clinical practice guidelines for serious illness in Kenya. Arch Dis Child (2008) 2.26
Defining childhood severe falciparum malaria for intervention studies. PLoS Med (2007) 2.22
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol (2005) 2.19